These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2361459

  • 1. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
    Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pedroncelli A, Tonnarelli GP.
    Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Mar; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K, Althoff PH, Harris A, Hofmeister-Wagner W, Schifferdecker E, Schöffling K.
    Med Klin (Munich); 1990 Dec 15; 85(12):700-6. PubMed ID: 2128367
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May 15; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF, Harris AG, Zhu XF, Deng JY.
    Clin Endocrinol (Oxf); 1990 Jun 12; 32(6):695-705. PubMed ID: 2200620
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY, Weissberger AJ, Marbach P, Lazarus L.
    Ann Intern Med; 1990 Feb 01; 112(3):173-81. PubMed ID: 2404445
    [Abstract] [Full Text] [Related]

  • 18. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW, Uitterlinden P, del Pozo E.
    J Clin Endocrinol Metab; 1987 Oct 01; 65(4):703-10. PubMed ID: 2888785
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ.
    J Clin Endocrinol Metab; 1988 Jan 01; 66(1):16-23. PubMed ID: 2891720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.